In a Phase 1 clinical trial, Queensland researchers have found that patients who received a cellular
immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) on average survived longer than would have been expected without the treatment.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
